Summary
Acute renal failure (ARF) was associated with increased urinary thromboxane (TXA2) excretion and lessened excretion of sodium (UNaV) and fractional excretion of sodium (FENa%). The inhibitor of thromboxane A2-synthetase OKY-046 enhanced sodium excretion and fractional excretion of sodium in normal and saline loaded animals whereas it partially prevented the reduction in sodium excretion and creatinine clearance and significantly increased fractional excretion of sodium in glycerol treated rats suggesting a partial protection against the development of acute renal failure.
References
Lifschitz, M. D., Kidney Int.19 (1981) 781.
Gerber, J.G., Nies, A.S., Friesinger, G.C., Gerkens, J.F., Branch, R.A., and Oates, J.A., Prostaglandins16 (1978) 519.
Johnston, H.H., Herzog, J.P., and Lauler, D.P., Am. J. Physiol.213 (1967) 939.
Papanikolaou, N., Mountokalakis, T., Bariety, J., and Milliez, P., J. Pharmac.7 (1976) 491.
Shimizu, K., Kurosawa, T., Maeda, T., and Yoshitoshi, Y., Jap. Heart J.AO (1969) 437.
Papanikolaou, N., Mountokalakis, T., Safar, M., and Milliez, P., Nephron18 (1977) 21.
Papanikolaou, N., Safar, M., Hornych, A., Fontaliran, F., Weiss, Y., Bariety, J., and Milliez, P., Clin. Sci. molec. Med.49 (1975) 459.
Shuster, A., Alexander, E., Lalone, R., and Levinsky, N., Am. J. Physiol.330 (1966) 1181.
Kokko, J.P., Kidney Int.19 (1981) 791.
Ayer, G., Grandchamp, A., Wyler, T., and Truniger, B., Circ. Res.29 (1971) 128.
Papanikolaou, N., Callard, P., and Bariety, J., Clin. Sci. molec. Med.49 (1975) 507.
Papanikolaou, N., Skoutelis, G., Papanikolaou, P., Paris, M., Dontas, A., Bariety, J., and Milliez, P., Experientia38 (1982) 476.
O'Connor, G., Bardgette, J., Lifschitz, M., Reineck, J., and Stein, J., Kidney Int.12 (1977) 531.
Eliahou, H., Brodman, R., and Friedman, E., Proc. Conf. ARF pp.265–279. DHEW Publ. (NIH) 74-608 Washington DC, 1973.
Oken, D.E., Cotes, S.C., Flamenbaun, W., Powell-Jackson, J.D., and Lever, A.F., Kidney Int.7 (1975) 12.
Blaine, E.H., Prostaglandins26 (1983) 805.
Kimberly, R.P., and Plotz, P.H., Kidney Int.19 (1981) 791.
Lifschitz, M.D., and Barnes, J.L., Am. J. Physiol.27 (1984) F714.
Mendal, A., and Miller, J., Prostagl. Leuk. Med.8 (1982) 361.
Papanikolaou, N., Hornych, A., Makrakis, S., Bariety, J., Weiss, Y., Safar, M., Meyer, P., and Milliez, P., Prog. Med.101 (1973) 271.
Werb, R., Clar, W.F., Lindsay, R.M., Jones, E.P., Turnbull, D.I., and Linton, A.L., Clin. Sci.55 (1978) 505.
Benabe, J.E., Klahr, S., Hoffman, M.K., and Morrison, A.R., Prostaglandins19 (1980) 333.
Sraer, J.D., Doleris, L., Delarue, F., Sraer, J., and Ardailou, R., Circ. Res.49 (1981) 775.
Ally, A.J., and Horrobin, D.F., Prostagl. Leuk. Med.4 (1980) 431.
Hamberg, M., Svenson, J., and Samuelsson, B., Proc. natn. Acad. Sci. USA72 (1975) 2994.
Iizuka, K., Akahane, K., Momose, D., Nalazawa, M., Tanouchi, T., Okada, T., Taniguchi, K., Miyamoto, T., and Hayashi, M., J. med. Chem.24 (1139).
Granstrom, E., and Kindahl, H., Adv. Prostagl. Thromb. Res., vol. 5, p. 156. Ed. J.C. Frohlich. Raven Press, New York 1978.
Korteweg, M., De Boever, J., Vandevivere, D., and Verdonk, G., Adv. Prostagl. Thromb. Res., vol. 6, p. 201. Eds B. Samuelsson, W. Ramwell and R. Paoletti, Raven Press, New York 1980.
Strickland, D.M., Brennecke, S.P., and Michell, M.D., Prostagl. Leuk. Med.9 (1982) 491.
Papanikolaou, N., Experientia28 (1972) 275.
Jubiz, W., Terashima, R., and Anderson, F.L., Adv. Prostagl. Thromb. Res., vol. 2, p. 603. Eds B. Samuelsson and R. Paoletti. Raven Press, New York 1976.
Herbaczynska-Cendro, K., and Vane, J.R., Nature247 (1974) 492.
Sato, M., Abe, T., Haruyama, T., et al., Prostagl. Leuk. Med.8 (1982) 199.
Shimizu, K., Yamamoto, M., and Yoshitoshi, Y., Jap. Heart J.14 (1973) 140.
Watson, M.L., Cumming, A.D., Lambie, A.T., and Oates, J.A., Clin. Sci.68 (1985) 537.
Author information
Authors and Affiliations
Additional information
Acknowledgment. This work was supported by the Public Benefit Foundation ‘Alexander S. Onassis’ (G-73). We thank ONO Pharmaceutical Co. Ltd, Kissei Pharmaceutical Co. Ltd, Osaka, Japan, and Dr A Hornych for their generous donations of OKY-046 and anti6keto-PGF1a antibodies respectively.
Rights and permissions
About this article
Cite this article
Hatziantoniou, C., Papanikolaou, N. Renal effects of the inhibitor of thromboxane A2-synthetase OKY-046. Experientia 42, 613–615 (1986). https://doi.org/10.1007/BF01955558
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01955558